Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06106997
Other study ID # sCT-Feasibility
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date January 2024
Est. completion date August 2025

Study information

Verified date October 2023
Source University of Erlangen-Nürnberg Medical School
Contact Christoph Bert, Prof. Dr. rer. nat
Phone ++49(0)9131-85-44213
Email christoph.bert@uk-erlangen.de
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this observational study is to show the feasibility of an MRI-only workflow in brain radiotherapy. The main question it aims to answer is: - Is an MRI-only workflow based on deep learning sCTs feasible in clinical routine? Participants will be treated as in clinical routine, but treatment planning will be based on sCTs, that are generated from MRI images. The dosimetrical equivalence to the standard CT based workflow will be tested at several points in the study.


Description:

The purpose of this clinical study is to investigate the clinical feasibility of a deep learning-based MRI-only workflow for brain radiotherapy, that eliminates the registration uncertainty through calculation of a synthetic CT (sCT) from MRI data. A total of 54 patients with an indication for radiation treatment of the brain and stereotactic mask immobilization will be recruited. All study patients will receive standard therapy and imaging including both CT and MRI. All patients will receive dedicated RT-MRI scans in treatment position. An sCT will be reconstructed from an acquired MRI DIXON-sequence using a commercially available deep learning solution on which subsequent radiotherapy planning will be performed. Through multiple quality assurance (QA) measures and reviews during the course of the study, the feasibility of an MRI-only workflow and comparative parameters between sCT and standard CT workflow will be investigated holistically. These QA measures include feasibility and quality of image guidance (IGRT) at the linear accelerator using sCT derived digitally reconstructed radiographs in addition to potential dosimetric deviations between the CT and sCT plan. The aim of this clinical study is to establish a brain MRI-only workflow as well as to identify risks and QA mechanisms to ensure a safe integration of deep learning-based sCT into radiotherapy planning and delivery.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 54
Est. completion date August 2025
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Written informed consent - Patient older than 18 years - Tumor or metastases in the brain - Immobilization with stereotactic mask - Treatment on stereotactic linear accelerator (2.5 mm leafs) equipped with 2D/2D X-ray system Exclusion Criteria: - Metal in the body, metal implants, pacemakers or other patient-specific factors that are a contraindication to an MRI scan - Metal implants, pacemakers or other patient-specific factors associated with increased risk from an MRI scan - Renal insufficiency (eGFR < 60 ml/min), allergy or other patient-specific factors that constitute a contraindication to contrast administration - Renal insufficiency (eGFR < 60 ml/min), allergy or other patient-specific factors associated with an increased risk from contrast administration - Patients who are institutionalized in care facilities, prisons or other supervised facilities. - Patients under guardianship - Non-consenting patients - Pregnant or breastfeeding patients

Study Design


Intervention

Radiation:
brain radiotherapy
brain radiotherapy planned on synthetic CTs

Locations

Country Name City State
Germany Erlangen, Universitätsklinikum Strahlenklinik Erlangen

Sponsors (1)

Lead Sponsor Collaborator
University of Erlangen-Nürnberg Medical School

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of patients that can successfully be treated in an MRI-only workflow All criteria have to be met for the MRI-only workflow to be classified as successful:
Verification criteria that will be assessed:
Can the sCT be generated and is the sCT clinically utilizable?
Are the three rotations needed for CT-MRI registration each = 3°?
Can a treatment plan be generated and verified using the sCT?
Is the dosimetric difference between sCT and CT based treatment plan in the planning target volume = 3%?
Is the dosimetric difference between the sCT and CT based treatment plan in affected organs at risk (receiving > 10% of prescribed dose) = 3%?
Are the couch correction parameters during patient positioning in the rotational degrees of freedom = 3°?
12 month
Secondary Reasons that lead to unfeasibility of an MRI-only workflow Presence (Yes/No) of individual reasons responsible for the unfeasibility of the MRI-only workflow, as assessed with a predefined checklist. 12 month
Secondary Dosimetric differences between MRI-only and standard workflow for radiotherapy treatment planning Paired difference in Dose-volume-histogram parameters (Target coverage, mean, median, near maximum and minimum dose) between MRI-only and standard radiotherapy treatment workflow. 12 month
Secondary Measurement of intra-MRI patient positional changes Patient shift (vector magnitude) and rotational errors occuring during the course of MRI acquisition due to patient movement, as assessed by rigid registration of the last acquired MRI sequence in reference to the first sequence. 12 month
Secondary Organ at risk contouring accuracy on MRI data Similarity of organ at risk segmentations defined in MRI compared to reference segmentations defined in CT as assessed by the volumetric and surface Dice score, as well as mean surface and Hausdorff distances. 12 month
See also
  Status Clinical Trial Phase
Recruiting NCT06057168 - Performance of Elucirem® in DSC-MRI Perfusion of Brain Gliomas Phase 3
Recruiting NCT04427384 - Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
Completed NCT03323450 - Cognitive Remediation Therapy for Brain Tumor Patients: Improving Working Memory N/A
Completed NCT00241670 - Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid Phase 3
Not yet recruiting NCT01445691 - More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery Phase 2
Completed NCT02599142 - Comparing Immobilisation Shells in Cranial Radiotherapy N/A
Recruiting NCT06282562 - FeelFit: High-intensity Interval Training to Improve Self-reported Physical Fitness in Brain Tumor Patients N/A
Recruiting NCT06322342 - Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent Phase 2
Completed NCT00001574 - A Pilot Study of 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Pediatric Patients With Primary and Metastatic Brain Tumors
Completed NCT04365647 - Intra-operative Variation in Size of Brain Tumors After Craniotomy
Not yet recruiting NCT06185686 - Radiation Induced Alterations in Resting State Brain Networks in Pediatric Brain Tumor Patients
Withdrawn NCT04776980 - Multimodality MRI and Liquid Biopsy in GBM Early Phase 1
Completed NCT03262636 - Two-Part Study to Evaluate the Safety and Efficacy of Image Guided Surgery Using Indocyanine Green for Intramolecular Imaging of Nervous System Tumors Compared to Standard of Care, (TumorGlow) Phase 1
Active, not recruiting NCT02006407 - A Pilot Study to Evaluate Neurocognitive Injury and Longitudinal Changes in White Matter During Radiation Therapy in Children With Primary Brain Tumors N/A
Recruiting NCT03213002 - Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM Phase 1/Phase 2
Recruiting NCT05775458 - Glutamate Excitotoxicity and Its Role in Glioblastoma Biology
Terminated NCT04901806 - Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors Phase 1
Recruiting NCT03373487 - Cognitive Rehabilitation in Brain Tumor Patients After Neurosurgery N/A
Recruiting NCT05254197 - SeOuL cOhort of Brain Tumor MONitoring Study (SOLOMON)
Recruiting NCT05092802 - The Efficacy of HLX208 (BRAF V600E Inhibitor) for Refractory Primary Brain Tumors With BRAF Mutation After First-line Treatment Phase 2